Woo, Xing Yi http://orcid.org/0000-0002-5980-4383
,
Giordano, Jessica http://orcid.org/0000-0003-0204-8158
Srivastava, Anuj
Zhao, Zi-Ming
Lloyd, Michael W.
de Bruijn, Roebi
Suh, Yun-Suhk
Patidar, Rajesh
Chen, Li
Scherer, Sandra
Bailey, Matthew H.
Yang, Chieh-Hsiang
Cortes-Sanchez, Emilio
Xi, Yuanxin
Wang, Jing http://orcid.org/0000-0002-5398-0802
Wickramasinghe, Jayamanna
Kossenkov, Andrew V.
Rebecca, Vito W.
Sun, Hua
Mashl, R. Jay
Davies, Sherri R. http://orcid.org/0000-0002-7141-8354
Jeon, Ryan
Frech, Christian
Randjelovic, Jelena
Rosains, Jacqueline
Galimi, Francesco
Bertotti, Andrea
Lafferty, Adam
O’Farrell, Alice C. http://orcid.org/0000-0002-6732-2966
Modave, Elodie
Lambrechts, Diether http://orcid.org/0000-0002-3429-302X
ter Brugge, Petra
Serra, Violeta http://orcid.org/0000-0001-6620-1065
Marangoni, Elisabetta http://orcid.org/0000-0002-3337-6448
El Botty, Rania
Kim, Hyunsoo
Kim, Jong-Il http://orcid.org/0000-0002-7240-3744
Yang, Han-Kwang
Lee, Charles
Dean, Dennis A. II http://orcid.org/0000-0002-7621-9717
Davis-Dusenbery, Brandi
Evrard, Yvonne A. http://orcid.org/0000-0002-3475-4850
Doroshow, James H.
Welm, Alana L. http://orcid.org/0000-0002-1412-1351
Welm, Bryan E.
Lewis, Michael T.
Fang, Bingliang
Roth, Jack A. http://orcid.org/0000-0002-8955-1313
Meric-Bernstam, Funda
Herlyn, Meenhard http://orcid.org/0000-0003-0839-0739
Davies, Michael A. http://orcid.org/0000-0002-0977-0912
Ding, Li
Li, Shunqiang
Govindan, Ramaswamy
Isella, Claudio
Moscow, Jeffrey A. http://orcid.org/0000-0002-0479-1693
Trusolino, Livio http://orcid.org/0000-0002-6379-3365
Byrne, Annette T.
Jonkers, Jos http://orcid.org/0000-0002-9264-9792
Bult, Carol J.
Medico, Enzo http://orcid.org/0000-0002-3917-2438
Chuang, Jeffrey H. http://orcid.org/0000-0002-3298-2358
,
Article History
Received: 30 November 2019
Accepted: 18 November 2020
First Online: 7 January 2021
Change Date: 20 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-021-00811-4
Competing interests
: A.L.W. and B.E.W. receive a portion of royalties if the University of Utah licenses certain PDX models to for-profit entities. M.T.L. is a founder of, and equity stake holder in, Tvardi Therapeutics, a founder of, and limited partner in, StemMed and a manager in StemMed Holdings. He also receives a portion of royalties if the Baylor College of Medicine licenses certain PDX models to for-profit entities. J.A.R. serves as a consultant and received stocks from Genprex, and receives royalties from patents issued. F.M.-B. reports receiving commercial research grants from Novartis, AstraZeneca, Calithera, Aileron, Bayer, Jounce, CytomX, eFFECTOR, Zymeworks, PUMA Biotechnology, Curis, Millennium, Daiichi Sankyo, Abbvie, Guardant Health, Takeda, Seattle Genetics and GlaxoSmithKline, as well as grants and travel-related fees from Taiho, Genentech, Debiopharm Group and Pfizer. She also served as a consultant to Pieris, Dialectica, Sumitomo Dainippon, Samsung Bioepis, Aduro, OrigiMed, Xencor, The Jackson Laboratory, Zymeworks, Kolon Life Science and Parexel International, and an advisor to Inflection Biosciences, GRAIL, DarwinHealth, Spectrum, Mersana and Seattle Genetics. L.T. reports receiving research grants from Symphogen, Servier, Pfizer and Merus, and he is in the speakers’ bureau of Eli Lilly, AstraZeneca and Merck. J.J. reports receiving funding for collaborative research from Artios Pharma. He also serves as a Scientific Advisory Board member of Artios Pharma. The other authors declare no competing interests.